Calreticulin Antibody (FMC 75) - BSA Free

Western Blot: Calreticulin Antibody (FMC 75) [NBP1-97502] - Analysis of Calreticulin: Lane 1: HeLa (Heat Shocked), Lane 2: Vero.

Immunohistochemistry-Paraffin: Calreticulin Antibody (FMC 75) [NBP1-97502] - Analysis of human uterus tissue stained with Calreticulin, mAb (FMC 75) at 10ug/ml.

• Reactivity: Hu, Pm
• Applications: WB, ICC/IF, IHC, IP
• Clone: FMC 75
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Unconjugated
• Format: BSA Free
• Concentration: 1.0 mg/ml

Calreticulin Antibody (FMC 75) - BSA Free Summary

• Description: Novus Biologicals Mouse Calreticulin Antibody (FMC 75) - BSA Free (NBP1-97502) is a monoclonal antibody validated for use in IHC, WB, ICC/IF and IP. Anti-Calreticulin Antibody: Cited in 1 publication. All Novus Biologicals antibodies are covered by our 100% guarantee.
• Immunogen: Calreticulin Antibody (FMC 75) was developed against recombinant Calreticulin-maltose binding fusion protein.
• Marker: Endoplasmic Reticulum Marker
• Isotype: IgG1
• Clonality: Monoclonal
• Host: Mouse
• Gene: CALR
• Purity: Protein G purified

Applications/Dilutions

• Dilutions:
  • Immunocytochemistry/ Immunofluorescence 1:10-1:500
  • Immunohistochemistry 1:10-1:500
  • Immunohistochemistry-Paraffin 1:10-1:500
  • Immunoprecipitation 12.5 ug/ml
  • Western Blot 1:1000
• Theoretical MW: 63 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.

Reactivity Notes

Recognizes Primate Calreticulin.

Packaging, Storage & Formulations

• Storage: Store at -20C. Avoid freeze-thaw cycles.
• Buffer: PBS and 50% Glycerol
• Preservative: 0.09% Sodium Azide
• Concentration: 1.0 mg/ml
• Purity: Protein G purified

Alternate Names for Calreticulin Antibody (FMC 75) - BSA Free

• Autoantigen Ro
• CALR
• Calregulin
• Calreticulin
• cC1qR
• CRP55
• CRT
• Endoplasmic reticulum resident protein 60
• epididymis secretory sperm binding protein Li 99n
• ERp60
• FLJ26680
• grp60
• HACBP
• HEL-S-99n
• RO
• Sicca syndrome antigen A (autoantigen Ro; calreticulin)
• SSA
• Vasostatin

Background

Calreticulin, also called CALR, is an endoplasmic reticulum (ER) protein that functions as a calcium (Ca2+) buffering molecular chaperone (1-3). Together with calnexin and ERp57, calreticulin has a critical role in protein folding and quality control of newly synthesized glycoproteins (1-3). Calreticulin has many diverse functions beyond Ca2+ binding, including cell adhesion, lectin binding, apoptosis, nuclear transport, antigen presentation, and immune response (1-3). Specifically, calreticulin is part of the peptide-loading complex that resides on the ER membrane and is responsible for antigen loading onto MHC class I molecules (1-3). Calreticulin protein has a theoretical molecular weight of 46 kDa and is 417 amino acids (aa) in length (1-3). The protein has three main domains: the N-terminal lectin-like domain, the proline-rich P-domain, and the acidic C-domain which is followed by an ER-retention KDEL signal sequence (1-3).

Given its role in multiple biological processes, it makes sense that calreticulin is implicated in both healthy and disease states. Studies have found that calreticulin mutations were present in patients with myeloproliferative neoplasms (MFN) and essential thrombocythaemia (ET) (4). Calreticulin expression is typically upregulated in most cancer lines, however it is downregulated in some tissues including cervical carcinomas, prostate cancer, and human colon adenocarcinoma (3). High expression of calreticulin on cancer cells is related to tumor cell phagocytosis and is often correlated with, and counteracted by, elevated CD47 expression to prevent cancer cell phagocytosis (3). Calreticulin mutations can serve as a major diagnostic biomarker for MFN and ET and additionally the calreticulin gene may be a potential target for cancer therapeutics (3,4).

References

1. Michalak, M., Groenendyk, J., Szabo, E., Gold, L. I., & Opas, M. (2009). Calreticulin, a multi-process calcium-buffering chaperone of the endoplasmic reticulum. The Biochemical Journal. https://doi.org/10.1042/BJ20081847

2. Fucikova, J., Spisek, R., Kroemer, G., & Galluzzi, L. (2021). Calreticulin and cancer. Cell Research. https://doi.org/10.1038/s41422-020-0383-9

3. Sun, J., Mu, H., Dai, K., & Yi, L. (2017). Calreticulin: a potential anti-cancer therapeutic target. Die Pharmazie. https://doi.org/10.1691/ph.2017.7031

4. Prins, D., Gonzalez Arias, C., Klampfl, T., Grinfeld, J., & Green, A. R. (2020). Mutant Calreticulin in the Myeloproliferative Neoplasms. HemaSphere. https://doi.org/10.1097/HS9.0000000000000333

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for Calreticulin Antibody (NBP1-97502)(1)

Publication using NBP1-97502

• Sikorski K, Mehta A et al. A high-throughput pipeline for validation of antibodies. Nat Methods 2018-01-11 [PMID: 30377371] (Human)
  
  Details:
  Antibody validation based on denaturing gel electrophoresis of biotinylated cell lysates (PAGE) followed by mass spectrometry (MS) and antibody array analysis (MAP).

Bioinformatics

• Gene Symbol: CALR
• Uniprot:
  • P27797(Human)